International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 2 , ISSUE 2 ( May-August, 2011 ) > List of Articles


Metformin throughout Pregnancy in Women with Polycystic Ovary Syndrome: Safety and Advantages

Bharti Bansal, Rutvij Jay Dalal, P Palshetkar Nandita, D Pai Hrishikesh, Takhtani Manisha, Saxena Nidhi

Citation Information : Bansal B, Dalal RJ, Palshetkar Nandita P, Pai Hrishikesh D, Manisha T, Nidhi S. Metformin throughout Pregnancy in Women with Polycystic Ovary Syndrome: Safety and Advantages. Int J Infertil Fetal Med 2011; 2 (2):61-64.

DOI: 10.5005/jp-journals-10016-1019

License: CC BY-NC 4.0

Published Online: 01-04-2014

Copyright Statement:  Copyright © 2011; The Author(s).



To study the incidence of spontaneous abortions, congenital malformations, neonatal and maternal hypoglycemia after metformin therapy in pregnancy.


Prospective study.




56 women previously oligomenorrheic, nondiabetic women with polycystic ovarian syndrome, who conceived while on metformin.


Metformin 1 to 1.5 gm/day throughout pregnancy.

Main outcome

Incidence of 1st trimester abortions, gestational diabetes, teratogenicity and maternal complications, like gastritis and hypoglycemia.


On metformin, the incidence of 1st trimester abortion was 11% and the incidence of gestational diabetes was 7%, which is much lower than the incidence otherwise cited for PCOS women. No major congenital abnormalities were observed.


Metformin therapy in pregnancy reduces the otherwise high incidence of 1st trimester abortions, and gestational diabetes in PCOS women is tolerated well and is not found to be teratogenic.

PDF Share
  1. Diagnostic criteria for polycystic ovary syndrome: A rational approach. Polycystic Ovary syndrome. Blackwell Scientific, Cambridge, MA 1992;377-84.
  2. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54.
  3. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392-95.
  4. Metformin induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome. Metabolism 1999;48:511-19.
  5. Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovarian syndrome: A randomized, double blind, placebo-controlled trial followed by open long term clinical evaluation. J Clin Endocrinol Metab 2000;85: 139-46.
  6. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Fertil Steril 2004;81:19-25.
  7. Recurrent miscarriage: Aetiology, management and prognosis. Hum Reprod Update 2002;8:463-81.
  8. Polycystic ovaries and recurrent miscarriage: A reappraisal. Hum Reprod 2000;15: 612-15.
  9. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) study. Thromb Haemost 1997;77: 1096-103.
  10. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 1993;122: 606-15.
  11. Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. Fertil Steril 2006;85:1511e3-5.
  12. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006;22(12):680-84.
  13. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in women with polycystic ovary syndrome. Fertil Steril 2005;84:761-65.
  14. Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: A prospective clinical study. Fertil Steril 2008;90:727-30.
  15. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: Predictive role of autoantibodies. Diabetes Care 2006;29:607-12.
  16. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: A population-based study. Diabetes Care 2006;29:1915-17.
  17. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 2004;21:829-36.
  18. Metformin and gestational diabetes. Curr Diab Rep 2003;3:303-12.
  19. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res Oct 2008;34(5):832-37.
  20. Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. Eur J Pediatr 2009;168:203-06.
  21. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:1323-30.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.